Faculty & Staff

Paul Lockman

Inaugural Douglas D. Glover Chair of Pharmaceutical Sciences & Associate Center Director for Translational Research - MBRCC

2037D
Morgantown, WV 26506
prlockman@hsc.wvu.edu

P: 304-293-0944
F: 304-293-2576

Chair, Pharmaceutical Sciences

Pharmaceutical Sciences (SOP)
Faculty

Associate Center Director for Translational Research

Cancer Center Administration (MBRCC)
Admin

Program 3: Alexander B. Osborn Hematopoietic Malignancy and Transplantation
Member

Cancer Center Research Programs (MBRCC)
Admin



Teaching

Clinical Toxicology, Anatomy and Pharmacology

Details


Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, then went on to earn his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Douglas D. Glover Endowed Chair of Basic Pharmaceutical Sciences at West Virginia University School of Pharmacy. He also serves as the Associate Director for Translational Research at the Mary Babb Randolph Cancer Center. Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer. 
 

http://wvucancer.org/research/Members/Publications/LockmanP

Ten Most Recent:

Pharmacy student debt and return on investment of a pharmacy education.
Cain J, Campbell T, Congdon HB, Hancock K, Kaun M, Lockman PR, Evans RL.
Am J Pharm Educ. 2014;78(1):5

PMC3930253.

P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.
Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, Terrell TB, Bohn KA, Yasemin C, Grothe TR, Lockman JA, Lockman PR.
Front Pharmacol. 2013;4:136

PMC3816283.

Metastasis of breast tumor cells to brain is suppressed by phenethyl isothiocyanate in a novel metastasis model.
Gupta P, Adkins CE, Lockman PR, Srivastava SK.
PLoS One. 2013;8(6):e67278

PMC3695065.

Paclitaxel-Hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.
Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR.
Mol Cancer Ther. 2013;12(11):2389-2399.


Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier.
Mittapalli RK, Manda VK, Bohn KA, Adkins CE, Lockman PR.
J Neurosci Methods. 2013;219(1):188-195.


Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA.
Neuroimage. 2012;61(1):228-239.


Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, Castellino S, Rubin SD, Lockman PR, Steeg PS, Smith QR.
Pharm Res. 2012;29(3):770-781.

PMC3489161.

N-Aryl-substituted 3-(beta-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy.
Scott LE, Telpoukhovskaia M, Rodriguez-Rodriguez C, Merkel M, Bowen ML, Page BDG, Green DE, Storr T, Thomas F, Allen DD, Lockman PR, Patrick BO, Adam MJ, Orvig C.
Chemical Science. 2011;2(4):642-648.


3-D-QSAR and docking studies on the neuronal choline transporter.
Geldenhuys WJ, Allen DD, Lockman PR.
Bioorg Med Chem Lett. 2010;20(16):4870-4877.


Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter.
Geldenhuys WJ, Manda VK, Mittapalli RK, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD, Lockman PR.
Bioorg Med Chem Lett. 2010;20(3):870-877.

PMC2818856.

Recent Scientific Awards
TTUHSC President’s Young Investigator Research Award (2009)
TTUHSC School of Pharmacy, Distinguished Alumni Award; Excellence in Research (2010)
Invited Talk; Gordon Research Conference: Barriers of the CNS (2010): Drug delivery to metastatic brain tumors. Colby-Sawyer College, New Hampshire.
Invited Talk; Does Chemotherapy Reach Effective Concentrations for the Treatment of Brain Metastases of Breast Cancer? Medical Rounds – London Health Sciences Center. Invited Seminar and Discussion. London  Ontario, Canada
Invited Talk; Breast Cancer Center of Excellence, Invited Panelist and speaker National Breast Cancer Coalition Fund, Annual Advocacy Training Conference, Washington DC.(2009)
Invited Talk; Challenges and Opportunities to Deliver Drugs in Brain Metastases of Breast Cancer, Invited Seminar, MD Anderson Houston TX (2009)
Invited Talk; Workshop on Drug Delivery in Parkinson’s Disease; Circumventing the Blood-brain barrier (2008):Michael J. Fox Foundation and the Kinetics foundation. San Francisco, CA. 
 
Recent Educational Awards
American Association of Colleges of Pharmacy; Innovations in Teaching Award (2007)
Texas Higher Education Coordinating Board Star Award Finalist (2009)
TTUHSC President’s Excellence in Teaching Award (2008)
P3 Teacher of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007, 2008)
P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007)
P1 Teaching Team of the Year; Texas Tech University HSC, SOP (2004)

Current CV

Research


Research Interests
Chemotherapy distribution into brain tumors and metastases
Nanoparticle drug delivery to brain
Effects of nicotine and or smoking on drug distribution
 
Recent and Current Funding
biOasis; Drug Company Contract  “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer; Survival Project”
National Cancer Institute, National Institutes of Health, Bethesda, MD. 1R01CA166067-01A1 “Prevention and Treatment of Brain Micro-metastases of Breast Cancer”
NEKTAR Therapeutics; Drug company contract “Pharmacokinetics and efficacy of NEKTAR-102 in brain metastases of breast cancer”
biOasis; drug company contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer”
Department of Defense, Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter.
Department of Defense, Breast Cancer Research Program. # BC050006. Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer.
Microtransponder; Medical Device Grant “Feasibility of microstimulation for targeted BBB disruption.” 
Minority Health Research and Education Grant program. State of Texas Board of Higher Education; Minority Health Research and Education Grant. Innovations in Competency Education: Strengthening the Pipeline.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. Development of Novel Treatments for Nicotine Addiction.”